See more : Parker Drilling Company (PKDC) Income Statement Analysis – Financial Results
Complete financial analysis of Promore Pharma AB (publ) (PROMO.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Promore Pharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Corporate Resource Services, Inc. (CRRSQ) Income Statement Analysis – Financial Results
- Alpha Healthcare Acquisition Corp. III (ALPAW) Income Statement Analysis – Financial Results
- Scientia School, S.A. (MLSCI.PA) Income Statement Analysis – Financial Results
- Razor Labs (RZR.TA) Income Statement Analysis – Financial Results
- Nolato AB (publ) (NOLA-B.ST) Income Statement Analysis – Financial Results
Promore Pharma AB (publ) (PROMO.ST)
About Promore Pharma AB (publ)
Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 99.00K | 417.00K | 3.00K | 3.93M | 2.45M | 632.13K |
| Cost of Revenue | 15.94M | 15.31M | 18.21M | 20.30M | 24.45M | 10.94M |
| Gross Profit | -15.85M | -14.90M | -18.20M | -16.37M | -22.01M | -10.31M |
| Gross Profit Ratio | -16,005.05% | -3,571.94% | -606,733.33% | -416.78% | -899.36% | -1,630.34% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 7.11M | 5.99M | 7.20M | 5.78M | 9.53M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.70M | 7.11M | 5.99M | 7.20M | 5.78M | 9.53M |
| Other Expenses | 10.76M | 4.69M | 4.90M | 5.49M | 4.89M | -10.25M |
| Operating Expenses | 10.76M | 11.80M | 10.89M | 12.70M | 10.67M | -722.68K |
| Cost & Expenses | 26.70M | 27.11M | 29.10M | 33.00M | 35.12M | 10.22M |
| Interest Income | 16.00K | 78.00K | 235.00K | 293.00K | 0.00 | 1.25M |
| Interest Expense | 16.00K | 170.00K | 11.00K | 95.83K | 52.96K | 0.00 |
| Depreciation & Amortization | 228.49K | -112.00K | 1.14M | 1.22M | 1.22M | 1.22M |
| EBITDA | -26.60M | -26.69M | -27.96M | -27.85M | -31.46M | -8.37M |
| EBITDA Ratio | -26,871.72% | -6,401.44% | -931,933.33% | -709.10% | -1,285.73% | -1,323.47% |
| Operating Income | -26.60M | -26.58M | -29.09M | -29.07M | -32.68M | -9.58M |
| Operating Income Ratio | -26,871.72% | -6,374.58% | -969,800.00% | -740.09% | -1,335.48% | -1,516.02% |
| Total Other Income/Expenses | -16.00K | -78.00K | -311.00K | 203.59K | 193.15K | 1.15M |
| Income Before Tax | -26.62M | -26.77M | -29.41M | -28.87M | -32.48M | -8.43M |
| Income Before Tax Ratio | -26,887.88% | -6,420.14% | -980,166.67% | -734.90% | -1,327.58% | -1,333.91% |
| Income Tax Expense | -26.60M | 190.00K | 545.00K | -203.95K | -246.10K | -1.58M |
| Net Income | -26.62M | -26.96M | -29.95M | -28.66M | -32.48M | -8.43M |
| Net Income Ratio | -26,887.88% | -6,465.71% | -998,333.33% | -729.71% | -1,327.58% | -1,333.91% |
| EPS | -0.44 | -0.57 | -0.82 | -1.32 | -1.58 | -0.43 |
| EPS Diluted | -0.44 | -0.57 | -0.82 | -1.32 | -1.58 | -0.43 |
| Weighted Avg Shares Out | 60.71M | 47.69M | 36.43M | 21.39M | 20.24M | 19.60M |
| Weighted Avg Shares Out (Dil) | 60.71M | 47.69M | 36.43M | 21.71M | 20.53M | 19.60M |
Source: https://incomestatements.info
Category: Stock Reports